The biotechnology revolution has stimulated increased activity and has witnessed a remarkable pace in the research and development of vaccines and associated technologies for disease control through immunization. Many new diseases have recently become--or soon will be--vaccine preventable, and improvements to existing vaccines are appearing in rapid succession.

In recognition of this growth in the field, this 3-day conference has become the first major, international, non-commercial scientific forum devoted exclusively to the presentation and sharing of data and knowledge among the diverse disciplines of vaccinology. It serves as an annual forum for presenting and discussing the latest vaccine-related scientific data, results, and issues via symposia and panel discussions by expert faculty and through oral and poster presentations of submitted papers. The goal is to encourage communication between the "upstream" and "downstream" ends of the vaccine research and development pipeline: vaccine scientists and producers, public health officials, and medical personnel who administer vaccines.

To better serve these aims, the organizers have drawn upon suggestions solicited at the First and Second Annual Conferences on Vaccine Research. Without altering or diluting the broadly inclusive, yet intimate nature of previous conferences, the 2000 conference will incorporate more basic science, expand poster sessions, enhance networking opportunities, and implement more selective concurrent scheduling.

Keynote Address Explain the difference between disease eradication and disease elimination Name two existing diseases currently targeted for eradication in the world Name an existing disease with an effective vaccine for which a future eradication program is technically feasible. Mary Lou Clements-Mann Memorial Lecture in Vaccine Sciences: List two promising new vaccine technologies currently under development Describe two goals of the new Global Alliance for Vaccines and Immunization. The Economics of Vaccines: Industry-Public Health Interface Discuss how vaccines are priced Discuss how major vaccine initiatives are financed Global Control and Eradication of Diseases Using Tools Currently Available Discuss the global status of two of the following vaccine preventable diseases: polio, measles, and/or H. influenza disease List barriers to the use of current vaccines for diseases targeted for but not yet having achieved elimination Immunologic Responses at the Extremes of Life Discuss one potential mechanism for inadequate immunologic response to immunization at both extremes of life Discuss one vaccine strategy to overcome inadequate host response to vaccines at both extremes of life

Respiratory Vaccines on the Near Horizon Characterize the potential public health impact for three of the following vaccines: group A streptococcus, respiratory syncytial virus, influenza, and/or pneumococcal conjugated and non-conjugated vaccines. List the stage of development for one of the vaccines characterized above (eg., phase II clinical trials.) Vaccines for Sexually Transmitted Infections Enumerate two potential advantages of mucosal versus parenteral immunization Characterize the potential public health impact for two of the following vaccines: human papillomavirus, chlamydia, and/or Herpes simplex virus. Innate Immunity Identify two mechanisms of innate immunity Discuss how they might be exploited. Genomics and Vaccinology Define genomics and explain how it can assist in developing future vaccines. Discuss one problem in utilizing genomic data in constructing vaccine candidates Controversies in Vaccine Safety List the advantages and disadvantages of preservatives in biologicals. Discuss the results of epidemiologic studies seeking to determine if there is a relationship between autoimmune disease and vaccines. Discuss two major concerns regarding new cell substrates in the manufacture of vaccines.

• Researchers and Scientists
• Epidemiologists
• Microbiologists
• Immunologists
• Molecular Biologists
• Public Health Officials
• Physicians and Veterinarians
• Vaccine Manufacturers

• Becton Dickenson and Company
• Chiron Corporation
• Glaxo Wellcome, Inc.
• King/Monarch Pharmaceuticals
• Merck Vaccine Division
• North American Vaccine, Inc.
• Pasteur Mérieux Connaught
• SmithKline Beecham Pharmaceuticals
• Wyeth-Lederle Vaccines

The National Foundation for Infectious Diseases (NFID) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide Continuing Medical Education (CME) for physicians. NFID takes responsibility for the content, quality, and scientific integrity of this CME activity.

The National Foundation for Infectious Diseases (NFID) designates this CME activity for a maximum of 15.5 credit hours in Category 1 of the Physician's Recognition Award of the American Medical Association. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.

• Back to NFID-SPONSORED CONFERENCES